Lumexa Imaging Reports Q3 2026 Profitability and Raises Full-Year EPS Guidance
Lumexa Imaging (LMRI) reported strong third-quarter 2026 financial results, transitioning from a net loss in the prior year to a net income of $7.2 million. The company saw consolidated revenues grow 5% year-over-year to $272 million, driven by increased volumes at outpatient sites and a record high advanced modality mix, which now accounts for 38.2% of total system volume. Operational efficiency and debt reduction following IPO proceeds contributed to improved margins and lower interest expenses. Consequently, the company raised its full-year adjusted EPS guidance to a range of $0.86 to $0.90 per share. While management noted a potential 1% negative reimbursement outlook for Medicare in 2027, current growth in high-reimbursement PET volumes and successful de novo facility expansions support a positive near-term trajectory.
Topics: EBITDA EPS Guidance Free Cash Flow Outpatient Services Revenue Growth